Navigation Links
GeoVax Labs Reports 2012 First Quarter Financial Results
Date:5/15/2012

icate superior protection when compared to similar viral challenge studies for competitive vaccine designs currently in human clinical trials. We are therefore very excited about the potential for our vaccine."

Dr. McNally continued, "On the financial side, we continue to benefit from NIH/HVTN support of our human clinical trials and we are seeking additional government support to fund our internal research and development activities to expand the use of our technology against strains (clades) of the HIV virus affecting other areas of the globe. From December 2011 to March 2012, we raised a total of $2.7 million in equity capital to bolster our cash reserves."

Comment on Gilead Science's Truvada® Prevention SubmissionDr. McNally also commented on the recent news related to an advisory panel's recommendation that the FDA approve Gilead Science's submission of their anti-viral medication, Truvada, for prevention of HIV. "While any positive step towards the control of this deadly disease is greatly welcomed, we must continue the search for safe, cost-effective measures to prevent HIV transmission. The high cost of oral medications, patient compliance, and risk of medical side effects clearly suggest the best solution still lies with a preventive vaccine. GeoVax's preventive vaccine is considered a leading candidate for the version of the virus prevalent in North and South America, and Europe."

Financial ReviewGeoVax reported a net loss for the three months ended March 31, 2012 of $730,513, or $0.04 per share, based on 16.7 million weighted average shares outstanding. For the three months ended March 31, 2011, the Company reported a loss of $606,282, or $0.04 per share, based on 15.7 million weighted average shares outstanding.

The Company reported revenues of $854,063 for the three months ended March 31, 2012, related to its Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) grant from the National Institutes
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. GeoVax Labs CEO Update Letter to Shareholders
2. GeoVax Labs First Patient Inoculated in Phase 1/2 Clinical Trial for HIV/AIDS Therapeutic Vaccine
3. GeoVax Phase 2a Clinical Trial Completes Enrollment
4. GeoVax $3.6 Million Award Increased to $4.4 Million by U.S. Government
5. GeoVax Labs, Inc. Announces Second Quarter Financial Results
6. GeoVax Labs HIV/AIDS Vaccine Development Leadership to be Highlighted During 2011 World Vaccine Congress
7. GeoVax Announces Publication of Phase 1 Clinical Trial in The Journal of Infectious Diseases
8. GeoVax Launches a Second Clinical Site to Test the Therapeutic Benefit of its HIV Vaccine
9. David A. Dodd Appointed Chairman of the Board of GeoVax Labs
10. GeoVax Announces Expansion of Phase 2a Human HIV/AIDS Vaccine Trial
11. GeoVax Awarded Federal Grant Under the Qualifying Therapeutic Discovery Project Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014 /CNW/ - A new expert ... Canada , released today by the ... safe and effective medicines for children. Each year about ... children use at least one prescription drug. Much of ... from the authorized use), creating potential health risks. ...
(Date:9/18/2014)... 18, 2014  RXi Pharmaceuticals Corporation (NASDAQ: ... focused on discovering, developing and commercializing innovative ... RNA-targeted technologies, today announced that the Company,s President ... Cauwenbergh , will present at the 7 ... Wednesday, September 24, 2014 at 11:20 a.m. ...
(Date:9/18/2014)... and CHESTERBROOK, Pa. , Sept. 18, ... VVUS ) and Auxilium Pharmaceuticals, Inc. (Nasdaq: ... Drug Administration (FDA) has approved a supplemental new drug application ... only FDA-approved erectile dysfunction (ED) medication indicated to be taken ... STENDRA is a prescription medication in a class of ...
Breaking Medicine Technology:Studying medicines in children is always possible and is in their best interest, finds Expert Panel 2Studying medicines in children is always possible and is in their best interest, finds Expert Panel 3RXi Pharmaceuticals to Present at the 7th Annual BioPharm America Conference 2RXi Pharmaceuticals to Present at the 7th Annual BioPharm America Conference 3VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 2VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 3VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 4VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 5VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 6VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 7VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 8VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 9
... , , ... external defibrillators used worldwide in health care facilities, public places, or in the home may ... Administration warned today. , , , ... , , ...
... STOCKHOLM , April 27, 2010 Axelar AB, ... been,elected new chairman of the board and Ingemar Kihlstrom board ... , , ... have just secured 25 MSEK financing for the continued development of,Axelar,s anticancer ...
Cached Medicine Technology:FDA Warns Users About Faulty Components in 14 External Defibrillator Models 2FDA Warns Users About Faulty Components in 14 External Defibrillator Models 3Axelar's Board Strengthened 2Axelar's Board Strengthened 3
(Date:9/18/2014)... This past August, Narconon Louisiana New Life Retreat ... kissing booth during the West Feliciana Animal Humane Society fundraiser to ... loved animals my whole life and have always had animals as ... who needed a home. Supporting an animal shelter allows me ... home!” , The CEO of Narconon Louisiana was there not only ...
(Date:9/18/2014)... NC (PRWEB) September 18, 2014 Relias Learning, ... health and human services markets, today announced it has been ... fastest growing private companies in America. , In the three-year ... and moved up almost 2,000 spots on the Inc. 5000 ... 2012. , “The industries we serve continue to ...
(Date:9/18/2014)... September 18, 2014 The new ... boon to contractors and homeowners alike as it ... overtakes the home, causes potential health issues, and ... nationwide, the BuildClean system allows contractors to virtually ... and other standard remodeling tasks. , BuildClean removes ...
(Date:9/18/2014)... HealthDay Reporter WEDNESDAY, Sept. ... be associated with increased odds of developing Parkinson,s disease ... suggests. The study, which did not prove a ... that the migraine-Parkinson,s association was stronger in women with ... sign of a pending attack that includes flashes of ...
(Date:9/18/2014)... 2014 It is true that ... when building a successful brand or business online. ... has recently compared plenty of professional web hosting ... Arvixe and iPage are the best VPS hosting ... of web hosting. All-sized businesses or enterprises can ...
Breaking Medicine News(10 mins):Health News:Narconon New Life Retreat Supports Local Animal Shelter At Recent Fundraiser 2Health News:Relias Learning Named to Inc. 5000 List for Second Consecutive Year 2Health News:New BuildClean™ System Brings Livability Back to Home Remodeling 2Health News:New BuildClean™ System Brings Livability Back to Home Remodeling 3Health News:New BuildClean™ System Brings Livability Back to Home Remodeling 4Health News:Are Migraines in Middle Age Tied to Raised Parkinson's Risk Later? 2Health News:Are Migraines in Middle Age Tied to Raised Parkinson's Risk Later? 3Health News:Best Cheap Hosting USA: GreenGeeks, Arvixe And iPage Are The Best Hosting Suppliers In 2014 2
... Bolling Air Force Base in Washington D.C., as well as a lecture ... ... Washington, D.C. (Vocus) July 2, 2008 -- The Drug Enforcement Administration ... Richard Nixon, who through an Executive Order established a single unified command ...
... QuadraBloc™, a new and improved version of AmWay's MagnaBloc. , ... ... a long-popular form of pain management, is now available in a ... ,"QuadraBloc has already been released in the United States, and will ...
... will be October 24-26, 2008 at the Catholic Institute in Toulouse, ... knowledge, ideas, applications and prospective issues in an interactive and collaborative ... http://www.ifats08.org for details. , ... Carmel, IN (PRWEB) ...
... using a combination of drugs targeting different parts of ... with severe lupus involving the kidneys, according to a ... Society of Nephrology (JASN). , "In our study, ... therapy for inducing complete remission of class V+IV lupus ...
... Clearance of Uniquely Integrated Meter/Pump System with ... and Compatible Software, WEST CHESTER, Pa., July ... its OneTouch(R) Ping(TM) Glucose Management System,by the U.S. ... the first,full-feature insulin pump that wirelessly communicates with ...
... of 300 human genomes in just over six months. The ... of genetic code that will be read by researchers worldwide, ... and disease. Scientists will be able to answer questions unthinkable ... be transformed. , The amount of data is remarkable: ...
Cached Medicine News:Health News:New MagnaBloc™ Product Available from Gradient Medical 2Health News:2008 International Federation of Adipose Therapeutics and Science (IFATS) Conference Date Set 2Health News:2008 International Federation of Adipose Therapeutics and Science (IFATS) Conference Date Set 3Health News:'Multi-target' immune therapy improves outcomes of severe lupus nephritis 2Health News:OneTouch(R) Ping(TM) Glucose Management System Cleared by FDA 2Health News:OneTouch(R) Ping(TM) Glucose Management System Cleared by FDA 3Health News:15 human genomes each week 2Health News:15 human genomes each week 3
... 4.5x and 5.5x magnification., ,Higher magnification ... guarantees a true image. Edge to ... is ideal for intricate surgical applications. ... with an anti-reflective coating to produce ...
VACUETTE® Tube Holders should be used exclusively with VACUETTE® Blood Collection Needles as both components are designed for optimal compatibility with one another....
Inquire...
The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
Medicine Products: